Trade
Trading Type
Spot
Trade crypto freely
Alpha
Points
Get promising tokens in streamlined on-chain trading
Pre-Market
Trade new tokens before they are officially listed
Margin
Magnify your profit with leverage
Convert & Block Trading
0 Fees
Trade any size with no fees and no slippage
Leveraged Tokens
Get exposure to leveraged positions simply
Futures
Futures
Hundreds of contracts settled in USDT or BTC
Options
HOT
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Earn
Launch
Investment
Simple Earn
VIP
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Quant Fund
VIP
Top asset management team helps you profit without hassle
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-Stop Lending Hub
VIP Wealth Hub
New
Customized wealth management empowers your assets growth
Staking
Stake cryptos to earn in PoS products
BTC Staking
HOT
Stake BTC and earn 10% APR
ETH Staking
HOT
Stake ETH and earn 6% APR
GUSD Minting
New
Use USDT/USDC to mint GUSD for treasury-level yields
Soft Staking
Earn rewards with flexible staking
More
- Trending TopicsView More
41.3K Popularity
43.4K Popularity
44.5K Popularity
38K Popularity
6.4K Popularity
- Pin
- 🎯 To further enhance the user experience on Gate Square, we sincerely invite you to take part in our first User Experience Survey 👉 https://www.gate.com/questionnaire/7086
✅ Reward: Complete the survey for a chance to win—10 lucky participants will receive a Gate X Red Bull Bottle
🙏 Thank You: Every piece of feedback helps us improve Gate Square. Your support and participation mean a lot!
📅 Survey Period: Sep 19 – Oct 9 - 💥 Gate Square Event: #PostToWinPORTALS# 💥
Post original content on Gate Square related to PORTALS, the Alpha Trading Competition, the Airdrop Campaign, or Launchpool, and get a chance to share 1,300 PORTALS rewards!
📅 Event Period: Sept 18, 2025, 18:00 – Sept 25, 2025, 24:00 (UTC+8)
📌 Related Campaigns:
Alpha Trading Competition: Join for a chance to win rewards
👉 https://www.gate.com/announcements/article/47181
Airdrop Campaign: Claim your PORTALS airdrop
👉 https://www.gate.com/announcements/article/47168
Launchpool: Stake GT to earn PORTALS
👉 https://www.gate.com/announcements/articl - 🌕 Gate Square · Creator Incentive Program Day 10 Topic– #Fed Cuts Rates By 25 Bps# !
Share trending topic posts, and split $5,000 in prizes! 🎁
👉 Check details & join: https://www.gate.com/campaigns/1953
💝 New users: Post for the first time and complete the interaction tasks to share $600 newcomer pool!
🔥 Day 10 Hot Topic: Fed Cuts Rates By 25 Bps
The Fed lowered its benchmark rate by 25 basis points to 4.00%–4.25%, in line with market expectations. This marks the restart of the rate-cut cycle since the pause last December. Lower rates often boost liquidity and risk appetite, which could be - 🚀 Gate Square Newbie Village · Episode 1 ✖️ @Ryakpanda Community
Let’s cheer on crypto beginners together!
📚 Learn trading tips ｜ 🎯 Unlock newbie perks ｜ 🤝 Grow with the community
⏰ Event Date: Sept 17 – Sept 24
How to Join:
1️⃣ Follow Gate_Square + Ryakpanda
2️⃣ Post on Gate Square with the hashtag #GateNewbieVillage#
3️⃣ Share your trading insights or newbie experiences
🎁 Rewards
3 lucky winners → Gate X RedBull Tumbler + $20 Futures Trial Voucher
If merchandise cannot be shipped, it will be replaced with a $30 Futures Voucher
✨ You’re not alone—join #GateNewbieVillage# today!
Rongchang Bio responds to Pfizer's $200 million impairment of Vidisutuximab: Pfizer's conclusion is based on market competition environment.
On February 7th, Jinshi Data reported that Rongchang Biology responded to the reporter's inquiry about the devaluation of its vedolizumab (RC48) by its partner Pfizer, which amounted to a reduction of 200 million US dollars. Rongchang Biology stated that this devaluation is due to changes in the market competitive environment compared to the time of the transaction, and some indications for vedolizumab have not progressed as expected, resulting in a decrease in expected value compared to the transaction time. This conclusion was made by Pfizer based on its judgment of the market competitive environment. Previously, in August 2021, Rongchang Biology authorized the overseas rights of its HER2ADC (antibody-drug conjugate) vedolizumab to ADCleading company Seagen. In 2023, Seagen was acquired by Pfizer. Currently, Pfizer is advancing the indication of vedolizumab for urothelial carcinoma overseas.